CAMP
CAMP4 THERAPEUTICS CORPORATION
4.20$
-1.7%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +89.7% | +6.1% | +16.0% | +27.6% | -17.9% | -10.9% | -8.9% | -74.5% | -46.4% | +42.5% | +50.4% | |
| – | +134.5% | -30.8% | +33.5% | +46.3% | -41.0% | -9.5% | -10.1% | -56.4% | -52.6% | +65.9% | +71.9% | |
| – | +307.8% | -32.8% | +41.5% | +93.4% | -58.1% | -14.6% | -0.6% | -8.7% | -53.9% | +66.9% | +71.0% | |
| – | +414.2% | -56.0% | +55.3% | +75.6% | -60.8% | -14.6% | -0.6% | -8.7% | -53.9% | +66.9% | +71.0% | |
| – | +3.2% | +36.4% | +6.2% | +9.1% | -7.4% | -6.1% | -13.7% | -98.8% | -34.8% | -75.6% | +43.5% | |
| – | -10.4% | +75.0% | +24.0% | -11.8% | +14.8% | -12.6% | -37.3% | +18.4% | – | – | – | |
| – | +6.6% | +342.1% | +0.0% | +10.7% | +31.6% | -11.2% | -0.5% | +0.2% | – | – | – | |
| – | -24.7% | +295.2% | -22.0% | -10.1% | -2.7% | -15.1% | -15.2% | -19.3% | – | – | – | |
| – | +280.5% | +25.0% | +12.5% | +45.2% | -10.1% | -4.3% | -6.0% | -44.1% | -0.8% | -91.5% | +362.3% | |
| – | +5.4% | +54.6% | +24.7% | -12.5% | +45.3% | -11.6% | -11.6% | -91.6% | -1.7% | +22.9% | +61.6% | |
| – | +1,080.9% | +61.1% | +193.5% | +14.4% | +2.5% | -71.0% | -29.3% | -69.4% | +29.0% | +0.9% | -90.7% | |
| – | +3.9% | +21.4% | +17.2% | +12.5% | -28.7% | +29.5% | -16.4% | -93.0% | -51.6% | +16.1% | -85.0% | |
| – | +25.1% | -13.4% | +21.3% | +3.4% | -32.9% | -28.0% | -19.3% | -196.7% | – | – | -24.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.1% | -2.8% | +0.6% | -2.3% | -4.6% | -95.6% | +2.5% | +2,257.3% | -66.4% | +60.9% | +55.8% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.